Heron Therapeutics Inc. (HRTX) is attracting investor attention as a commercial-stage biotechnology company with a portfolio of approved products and late-stage candidates designed to improve patient care.
Despite reporting a wider net loss in the third quarter of 2025, the company continues to deliver revenue growth across its units and reaffirmed full-year guidance, signaling confidence in its commercial momentum.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.